The Research and Development team at AbolerIS Pharma focuses on pioneering innovative therapeutic strategies to achieve immune tolerance. They work on the development and optimization of treatments such as the anti-CD45RC monoclonal antibody and IL-34 cytokine, aiming to selectively target and modulate immune responses in inflammatory, autoimmune, and degenerative diseases. This team utilizes their extensive expertise in regulatory T cells and tolerance mechanisms to advance clinical applications and translational research.